Skip to main content
. 2020 Sep 19;46:102512. doi: 10.1016/j.msard.2020.102512

Table 2.

Clinical data and medical history (n=1019 People with multiple sclerosis), stratified by age.

<=55 years >55 years
n (%) 512 (50%) 507 (50%)
CIS 10 (2) 8 (2)
RRMS 408 (80) 245 (48)
SPMS 66 (13) 155 (31)
PPMS 26 (5) 92 (18)
Unknown to participant 2 (0.4) 7 (1)
Patient-determined disease step (PDSS) score, median (1st quartile, 3rd quartile) 2 (0, 4) 4 (2, 5)
Taken DMT within past year
Yes
No
Don't know

417 (81)
88 (17)
7 (1)

331 (65)
166 (33)
10 (2)
DMTsa:
Glatiramer acetate
Interferon beta-1
Peginterferon beta-1a
Fingolimod
Siponimod
Dimethyl fumarate
Diroximel fumarate
Teriflunomide
Cladribine
Natalizumab
Rituximab
Ocrelizumab
Alemtuzumab
Otherb

35 (7)
21 (4)
3 (0.6)
58 (11)
3 (0.6)
52 (10)
0
20 (4)
6 (1)
44 (9)
21 (4)
134 (26)
7 (1)
5 (1)

48 (9)
23 (5)
4 (0.8)
23 (5)
5 (1)
35 (7)
3 (0.6)
25 (5)
4 (0.8)
23 (5)
17 (3)
104 (21)
0
5 (0.9)
MS relapse in last month
Yes
No
Don't Know

46 (9)
415 (81)
51 (10)

34 (7)
440 (87)
33 (7)
Hospitalized due to MS in 2019
Yes
No
Don't know

24 (5)
156 (30)
3 (0.6)

13 (3)
136 (27)
0
Ever hospitalized due to MS
Yes
No
Don't Know

183 (36)
322 (63)
7 (1)

149 (29)
350 (69)
8 (2)
Needed steroids in the last month
Yes
No
Don't Know

27 (5)
480 (94)
5 (1)

26 (5)
475 (94)
6 (1)
In-person neurologist visit in last 6 months
Yes
No
Don't Know

396 (77)
109 (21)
7 (1)

374 (74)
131 (26)
2 (0.4)
Medical history/comorbidities:
Asthma
Cancer (current)
Depression
Diabetes
Heart disease
Hypertension
Lung disease
Smoke cigarettes
Avg. cigarettes/day
83 (16)
6 (1)
229 (45)
18 (4)
11 (2)
81 (16)
14 (3)
41 (8)
12
44 (9)
29 (6)
193 (38)
35 (7)
43 (8)
183 (36)
28 (6)
23 (5)
12

a104 participants <=55 years of age did not have DMT data available. 184 participants >55 years of age did not have DMT data available. bIncludes ibudilast, mycophenolate mofetil and cyclophosphamide.